GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevi Therapeutics Inc (NAS:TRVI) » Definitions » EPS without NRI

Trevi Therapeutics (Trevi Therapeutics) EPS without NRI : $-0.29 (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Trevi Therapeutics EPS without NRI?

Trevi Therapeutics's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-0.08. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.29.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 45.70% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 35.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Trevi Therapeutics's EPS without NRI or its related term are showing as below:

TRVI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -13.2   Med: 27.6   Max: 45.7
Current: 45.7

During the past 7 years, Trevi Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 45.70% per year. The lowest was -13.20% per year. And the median was 27.60% per year.

TRVI's 3-Year EPS without NRI Growth Rate is ranked better than
89.1% of 1294 companies
in the Biotechnology industry
Industry Median: 4.7 vs TRVI: 45.70

Trevi Therapeutics's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.08. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.29.

Trevi Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-0.08. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.29.


Trevi Therapeutics EPS without NRI Historical Data

The historical data trend for Trevi Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trevi Therapeutics EPS without NRI Chart

Trevi Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -2.28 -1.81 -1.49 -0.45 -0.29

Trevi Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.06 -0.07 -0.08 -0.08

Competitive Comparison of Trevi Therapeutics's EPS without NRI

For the Biotechnology subindustry, Trevi Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trevi Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trevi Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Trevi Therapeutics's PE Ratio without NRI falls into.



Trevi Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Trevi Therapeutics  (NAS:TRVI) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Trevi Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Trevi Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Trevi Therapeutics (Trevi Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
195 Church Street, 16th Floor, New Haven, CT, USA, 06510
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Executives
Lisa Delfini officer: Chief Financial Officer C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FL. 14, NEW HAVEN CT 06510
Farrell Simon officer: Chief Commercial Officer C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
David J Clark officer: Chief Medical Officer 131 HARTWELL AVE, LEXINGTON MA 02421
Tpg Gp A, Llc 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Scott D Sandell 10 percent owner
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker director 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Forest Baskett 10 percent owner
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Jon Winkelried 10 percent owner C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Christopher Galletta officer: See Remarks 195 CHURCH STREET, FLOOR 14,, NEW HAVEN CT 06510